Alan B. Sandler, M.D.
- Email:
- click here
- Office:
- 503 494-6594
Professor
Background
Alan Sandler is a Professor of Medicine in the Division of Hematology & Medical Oncology, Department of Medicine, at Oregon Health & Science University in Portland, Oregon and is the DeArmond Chair for Clinical Cancer Research. After earning a B.S. in Pharmacy (cum laude) at the University of Toledo in Ohio and an M.D. at Rush Medical College in Chicago, Dr. Sandler completed an internship and residency in Internal Medicine at Yale-New Haven Hospital and a Fellowship in Medical Oncology at the Yale University School of Medicine in New Haven, Connecticut. His academic honors include membership in Alpha Omega Alpha and Rho Chi, the medical and pharmaceutical honor societies. Dr. Sandler is a member of the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group, where he serves as the Co-Chair of the Thoracic Committee. He is principal investigator or co-principal investigator of several therapeutic clinical trials that evaluate the activity of chemotherapeutic agents and/or combined-modality therapies in both small and non-small cell lung cancer as well as sarcoma. Dr. Sandler serves on the Editorial Boards of Clinical Lung Cancer and the Japanese Journal of Clinical Oncology, and is a reviewer for several journals including The New England Journal of Medicine, Journal of Clinical Oncology, Cancer Investigations, Cancer, the British Journal of Cancer, and European Respiratory Journal. Dr. Sandler is the author or co-author of more than 200 published articles, book chapters, reviews, and abstracts involving the pharmacology and clinical activity of chemotherapy and novel targeted agents, with a particular emphasis on lung cancer.
Selected Publications
"The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents,"
"Identifying barriers associated with enrollment of patients with lung cancer into clinical trials,"
"Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer,"
"Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: Results of an exploratory analysis,"
"An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases,"
